Результаты поиска

Antineoplastics : Lack of efficacy and infusion reaction: case report

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Thereafter, he received platelet transfusion. Afterwards, studies confirmed the diagnosis of moderately differentiated squamous lung cancer. … Worse still, he developed ineffective platelet transfusion and his bleeding symptoms had became more and more severe. Thereafter, he received salvage therapy with daratumumab 400mg at day 1, 800 mg at day 2, 1200 mg at days 8, 15, 22 [ route not stated ] in combination with dexamethasone. …

Клиническая реакция и переливание овечек, подвергшихся однополому переливанию крови.

Исследования, касающиеся сохранения крови и реагирования на переливание крови, недостаточны для румын. Мы провели оценку клинических проявлений овец, которые получили одно гомологическое переливание целой крови, сосредоточившись на реакциях на переливание. Eighteen Взрослые овцы подвергались одной флеботомии, с тем чтобы избавиться от нее. 40% общего объема крови, который был помещен в CPDA-1 мешки, а затем разделённые на G0, животные, которые получили свежую кровь, и G15 и G35, животные, которые получали кровь, хранимую для 15 или 35 Дни, соответственно. В ходе переливания были зарегистрирова

Совпадение в полном тексте источника
… Febrile reactions after platelet transfusion: the effect of single versus multiple donors Transfusion 1990 30 3 219 221 10.1046/j.1537-2995.1990.30390194340.x 2-s2.0-0025344588 1967118 19 Brubaker D. B. …

Factor X deficiency: An overlooked cause of bleeding in the newborn.

Inherited factor X (FX) deficiency is a rare autosomal recessive bleeding disorder, presenting with various bleeding manifestations ranging from nonspecific bruising to life-threatening intracranial hemorrhage. It is often misdiagnosed as hemorrhagic disease of the newborn. It is characterized by prolonged prothrombin time, as well as activated partial thromboplastin time, and needs FX level assay for definitive diagnosis. Here, we describe a case of a newborn with FX deficiency who presented with frank umbilical stump bleeding.

Acute promyelocytic leukaemia in a Nigerian patient-a case report depicting challenges in the management of haematological malignancies in Nigeria.

IntroductionHaematological malignancies (HMs) account for approximately 10% of all malignancies in sub-Saharan Africa (SSA), and their incidence is rapidly increasing. Successful management of these malignancies depends on early presentation, diagnosis and prompt initiation of treatment. However, in SSA and many low and middle-income countries, several barriers hinder the effective management of these malignancies. This case report of a patient with acute promyelocytic anaemia highlights the challenges in managing HM.Case summaryA 31-year-old woman presented to a primary health care centre wit

Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapy.

BackgroundOne of the main obstacles of providing home-based palliative care to transfusion-dependent hematology patients is the lack of home transfusions services. While healthcare professionals are concerned with safety and cost of home transfusions, the attitude of the patients toward home transfusions are mostly unknown.AimTo obtain quantitative data regarding the willingness and concerns of transfusion-dependent patients with hematological diseases toward the option of home transfusions.DesignA cross sectional survey including a self-administered questionnaire in one of the three main spok

Clinical applications of immunoglobulin: update.

Human immunoglobulin is the most used blood product in the clinical practice. Immunoglobulin applications have increased quickly since the elucidation of its immunomodulatory and antiinflammatory properties which turned this blood product into a precious tool in the treatment of numerous diseases that present with humoral immune deficiency or that cause immune system dysfunction. Currently, the approved indications for Ig are: primary immunodeficiencies, secondary immunodeficiencies (multiple myeloma or chronic lymphoid leukemia), Kawasaki syndrome, immune thrombocytopenic purpura, Guillain Ba

Novel therapies in thrombotic thrombocytopenic purpura.

Thrombotic thrombocytopenic purpura (TTP) is characterized by microangiopathic hemolytic anemia and a consumptive thrombocytopenia, as a result of severe deficiency of ADAMTS13. The standard of care of the acute episode is treatment with plasma exchange and immunosuppression. After the acute episode is resolved, patients face a significant risk of relapse and long-term complications associated with significant morbidity and even mortality. Novel treatments have been under development and will be discussed in this review. Caplacizumab, a nanobody that blocks the interaction between VWF and plat

Cold versus warm autoimmune hemolytic anemia in diffuse large B cell lymphoma: pathogenic and therapeutic implications: a case series.

BACKGROUND: Autoimmune hemolytic anemia-associated diffuse large B cell lymphoma is rare, with distinct pathogenic mechanisms and therapeutic responses in cold agglutinin syndrome (CAS) and warm autoimmune hemolytic anemia subtypes poorly characterized. This report highlights two novel cases demonstrating subtype-specific molecular drivers and treatment outcomes, underscoring the necessity for precision management. CASE PRESENTATION: Two patients presented with autoimmune hemolytic anemia: a 29-year-old Han male with cold agglutinin syndrome and a 37-year-old Han female with warm autoimmune h

A concise review on factors influencing the hematopoietic stem cell transplantation main outcomes.

Background and aimsAs a curative procedure, hematopoietic stemcell transplantation (HSCT) is an approved treatment for many malignant orbenign hematologic and non-hematologic diseases. There are different outcomes of HSCT, as well as several parameters influencing these outcomes.MethodsWe had searched scientific sources like Web ofScience and PubMed with a combination of keywords such as HSCT, engraftment,survival, outcomes, etc. Totally, 80 articles were included.ResultsHere we have reviewed the effective factors onmain outcomes of HSCT including engraftment, survival, graft versus hostdiseas

Интенсивность бриджирования связана с плохим гематопоиетическим восстановлением после терапии BCMA CAR-T для нескольких миелом.

Abstractchimeric антиген-рецептор (CAR) T-клеток (CAR-T) представляет собой значительный прогресс в лечении повторной/охлажденной множественной миеломы (RRMM). Однако продолжительный период времени от лейкофереза до фактического вливания CAR-T часто требует проведения цеховой терапии. Из-за ограниченных знаний о воздействии стыковки на клинические курсы и результаты после КАР-Т выбор вариантов лечения сопряжен с трудностями. В этом многоцентральном международном исследовании мы изучили влияние переходной терапии на гематопоиетическое восстановление 158 :: пациенты с RRMM лечатся антигенной тер

Совпадение в полном тексте источника
… CTX bridging resulted in a significantly higher rate of platelet transfusions during the late post–CAR-T period compared with the non-CTX group (OR, 5.63; P = .008), and numerically higher rates of patients receiving thrombopoietin receptor agonists and stem cell boosts ( Figure 3 E-G; supplemental Table …

Acute Promyelocytic Leukemia in a Woman with Thalassemia Intermedia: Case Report and Review of Literature on Hematological Malignancies in β-Thalassemia Patients.

Patients affected by transfusion-dependent β-thalassemia are prone to developing several clinical complications, mostly related to the iron overload. We report the case of a patient affected by transfusion-dependent β-thalassemia (TDT) developing acute promyelocytic leukemia (APL). In our case, the therapeutic management was significantly complicated not only by myocardial dysfunction, but also by the occurrence of the differentiation syndrome following all-trans retinoic acid (ATRA) administration. We carried out a careful revision of the current literature on the occurrence of hematological

37th International Symposium on Intensive Care and Emergency Medicine (part 2 of 3) : Brussels, Belgium. 21-24 March 2017

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia.

IO-202 is a humanized immunoglobulin G1 monoclonal antibody with high affinity and specificity for leukocyte immunoglobulin-like receptor B4 (LILRB4; ILT3), which is predominantly expressed in monocytes and monocytic blasts. IO-202 induces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis in vitro and in patients with leukemia. Herein, we present the phase 1a dose escalation data of IO-202 as monotherapy and in combination with azacitidine (AZA) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and R/R chronic myelomonocytic leukemia (C

How I treat microangiopathic hemolytic anemia in patients with cancer.

Microangiopathic hemolytic anemia (MAHA) with thrombocytopenia, suggests a thrombotic microangiopathy (TMA), linked with thrombus formation affecting small or larger vessels. In cancer patients, it may be directly related to the underlying malignancy (initial presentation or progressive disease), to its treatment, or a separate incidental diagnosis. It is vital to differentiate incidental thrombotic thrombocytopenia purpura or atypical hemolytic uremic syndrome in cancer patients presenting with a TMA, as they have different treatment strategies, and prompt initiation of treatment impacts outc

Совпадение в полном тексте источника
… Platelet transfusions may be given for severe thrombocytopenia in a case of cancer-associated TMA, based on the clinical picture and following usual platelet transfusion thresholds, unlike in TTP, where platelet transfusions are usually avoided because of risk of exacerbating microthrombotic complications …

Effects of short-term pretreatment with atorvastatin on mobilization of hematopoietic progenitor cells: A double-blind, randomized, controlled trial.

BackgroundDespite recent advances in mobilization techniques, a considerable portion of patients fail to mobilize sufficient number of cells for successful autologous stem cell transplantation. There are several studies available that have demonstrated enhanced mobilization of endothelial progenitor cells with atorvastatin. Therefore, this prospective trial was conducted to evaluate the mobilizing effect of atorvastatin on hematopoietic progenitor cells.Subjects and methodsForty-four autologous HSCT candidates were randomized in a double-blind controlled trial to receive atorvastatin 40 mg dai

Совпадение в полном тексте источника
… transfusion with platelet counts > 20,000/mm 3 after transplantation, while PMN engraftment was defined as the first of three consecutive days with PMN count > 500/mm 3 post-transplantation. … Apart from the inability of atorvastatin to mobilize more HPCs into peripheral circulation, it seems that the function of these cells has not been affected and the study groups were similar in their requirements for packed RBC or platelet transfusion. …

Уязвимость хост-Марроу до появления в CD19- и BCMA-Directed CAR T-Cell Terrapy: Клональная гематопоисис, гематотоксичность и терапия, связанная с Myeloid Neoplasia.

CD19- и B-клеточные антигены созревания (BCMA) на основе химерика антигенного рецептора T-клетка (CAR T-клетка) улучшили результаты в рецидивированных или рефрактных лимфоидных магнентов B-клеток и множественной миеломы, но поздние гематологические осложнения становятся все более актуальными по мере расширения выживших. В настоящем докладе рассматривается вопрос о том, каким образом предвыборный клоновый гематопоисис (CH), клональный гематопоисис неопределённого потенциала (CHIP), клональная цитопенсия неопределенного значения (CCUS), резерв костного мозга, предварительное генотоксичное воздей

Changes in treatment landscape of relapsed or refractory multiple myeloma and their association with mortality: Insights from German claims database.

ObjectivesEmerging treatments for relapsed or refractory multiple myeloma (rrMM) have led to increasing options for many patients. This study aimed to assess changes in utilization of these options in Germany with a focus on modern triplet regimens including new agents, such as carfilzomib, ixazomib, elotuzumab and daratumumab, and to evaluate whether this had an impact on rrMM-related outcomes over time.MethodsThe study population consisted of 1255 rrMM patients who were assigned to one of the following 6 treatment groups: immunomodulatory drug (IMiD)-based doublets, proteasome inhibitor (PI)

Совпадение в полном тексте источника
… The unadjusted event rates per person‐year of all count outcomes but the number of platelet transfusions was lower in cohort 2017 compared to cohort 2014. … For the outcomes pneumonia, thrombosis, and platelet transfusions, the number of events was too low to perform a valid comparison between cohorts in the prespecified age subgroups. …

Pancytopenia Concurrent With Metabolic Encephalopathy.

Pancytopenia is a decrease in the number of cells in all peripheral blood cell lines and has been associated with anemias, cancers, chemotherapy, infections, and nutritional deficiencies. However, pancytopenia concurrent with encephalopathy is rare and not well-studied. We present a case of pancytopenia concurrent with metabolic encephalopathy. An 81-year-old female patient presented to the emergency department for two weeks of increased fatigue and hypersomnolence. The patient had trouble staying awake during the initial physical exam, and her laboratory results were significant for pancytope

Pathology Competencies in Medical Education and Educational Cases: Update 2023.

Pathology is a core component of medical school curricula because understanding the pathogenesis of the disease is foundational both for diagnostic efficiency and optimal use of ancillary resources in patient care. The Pathology Competencies for Medical Education (PCME) were developed as a national resource of expectations of pathology knowledge for medical students. The PCME are composed of three competencies: disease mechanisms and processes, organ system pathology, and diagnostic pathology and therapeutic pathology. The learning goals and learning objectives of the PCME that were first publ

Evidence for the use of intravenous immunoglobulins--a review of the literature.

Intravenous immunoglobulins (IVIg) were first introduced in the middle of the twentieth century for the treatment of primary immunodeficiencies. In 1981, Paul Imbach noticed an improvement of immune-mediated thrombocytopenia, in patients receiving IVIg for immunodeficiencies. This opened a new era for the treatment of autoimmune conditions with IVIg. Since then, IVIg has become an important treatment option in a wide spectrum of diseases, including autoimmune and acute inflammatory conditions, most of them off-label (not included in the US Food and Drug Administration recommendation). A panel